Bavarian Nordic initiates Sierra Leone Ebola vaccine study

Bavarian Nordic started their safety and immunogenicity study for their Ebola vaccine, a combination of their MVA-BN® Filo vaccine and their Ad26.ZEBOV vaccine, in Sierra Leone Friday.

The first phase of the EBOVAC-Salone study has been initiated and includes approximately 40 volunteers aged 18 and older. Once the second phase initiates, approximately 400 volunteers from several age groups will receive doses of the vaccines.

This study acts as a parallel track to similar studies being conducted in the United States, Africa and Europe. Studies in the U.K. were the first to begin and they were followed by several in Africa. Janssen, parent company to Crucell, reported positive preliminary results to the U.S. Food and Drug Administration (FDA). Phase 2 studies began in France and the U.K. in July of this year.

“The initiation of EBOVAC-Salone marks an important milestone for our joint program with Janssen,” President and CEO of Bavarian Nordic Paul Chaplin told Bio Prep Watch. “It is a significant step forward in the development of a vaccine against Ebola. It is remarkable how far the program has moved, which has only been possible due to the commitment and dedication shown by both Janssen and our employees in terms of the progress we have made in manufacturing bulk vaccine for almost 2 million doses and initiating this study within a year of joining forces.”

Organizations in this Story

Bavarian Nordic U.S. Food and Drug Administration (FDA)

Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.